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Abstract 
Background 
Early (B24 h) systemic procalcitonin (PCT) levels are predictive for unfavorable neurological outcome in patients 
after out-of-hospital cardiac arrest (OHCA). Subarachnoid hemorrhage (SAH) due to aneurysm rupture might 
lead to a cerebral perfusion stop similar to OHCA. The current study analyzed the association of early PCT levels 
and outcome in patients after SAH. 
Methods 
Data from 109 consecutive patients, admitted within 24 h after SAH, were analyzed. PCT levels were measured 
within 24 h after ictus. Clinical severity was determined using the World Federation of Neurological Societies 
(WFNS) scale and dichotomized into severe (grade 4–5) and non-severe (1–3). Neurological outcome after 3 
months was assessed by the Glasgow outcome scale and dichotomized into unfavorable (1–3) and favourable (4–
5). The predictive value was assessed using receiver operating curve (ROC) analysis. 
Results 
Systemic PCT levels were significantly higher in patients with severe SAH compared to those with nonsevere 
SAH: 0.06 ± 0.04 versus 0.11 ± 0.11 lg/l (median ± interquartile range; p < 0.01). Patients with unfavorable 
outcome had significantly higher PCT levels compared to those with favorable outcome 0.09 ± 0.13 versus   
0.07 ± 0.15 ng/ml   (p < 0.01).   ROC   analysis showed an area under the curve of 0.66 (p < 0.01) for 
PCT, which was significantly lower than that of WFNS with 0.83 (p < 0.01). 
Conclusions   
Early PCT levels in patients with SAH might reflect the severity of the overall initial stress response. However, 
the predictive value is poor, especially compared to the reported predictive values in patients with OHCA. Early 
PCT levels might be of little use in pre- dicting neurological outcome after SAH. 
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Introduction  
Current evidence suggests that treatment of cerebral vasospasm (CVS) alone does not avoid the occurrence of 
neuronal injury, i.e., delayed cerebral ischemia (DCI), with consequent poor outcome in patients with 
aneurysmal subarachnoid hemorrhage (aSAH) [1, 2]. More recently, mechanisms of early brain injury have 
moved center stage in the research focus. It has been suggested that these mechanisms evolve with time and 
contribute to the path- ogenesis of DCI [3, 4]. The rupture of an aneurysm and consequent release of blood into 
the subarachnoid space leads to an abrupt increase of the intracranial pressure (ICP), which is suggested to cause 
a brief cerebral perfu- sion arrest [4]. 
Out-of-hospital cardiac arrest (OHCA) is associated with brief cerebral perfusion stop as well. More recently, 
early elevated systemic procalcitonin (PCT) levels have been described to accurately predict unfavorable neuro- 
logical outcome after OHCA [5–7]. Increased PCT levels have been sparsely described with regard to the course 
of illness after aSAH [8, 9]. However, the prognostic value of early PCT levels in patients with aSAH is 
unknown. The current study intended to evaluate the prognostic value of early PCT levels on the neurological 
outcome after aSAH. 
 
 
Materials and Methods  
The database consisted of prospectively collected data of 
231 patients with confirmed aSAH, admitted at the Neurocritical Care Unit, University Hospital Zurich (an 
academic tertiary care center), during a 3-year period, from 
2007 to 2009. In brief, the diagnosis was based on either CT or catheter angiography. The clinical severity at 
time of admission was assessed according to the World Federation of Neurological Surgeons (WFNS) grading 
[10]. The radiological severity was assessed based on the Fisher grading [11]. All patients were treated according 
to a standardized treatment protocol as previously described [12, 13].  Neurological outcome was assessed 3 
months after aSAH in the outpatient clinic according to the Glas- gow outcome scale (GOS). For the current 
study only patients with admission and PCT level measured within 24 h after ictus were included. Patients 
with rebleeding after admission were also excluded. The study was approved by the local ethics committee. 
PCT measurements were performed by the Institute of Clinical Chemistry, University Hospital Zurich, using an 
electrochemiluminescence immunoassay. Blood sampling and measurements were performed in terms of clinical 
routine, i.e., no additional blood sampling was performed. Having a potential influence on the PCT levels, we 
assessed the presence of a systemic inflammatory response syndrome (SIRS) and pneumonia at time of 
admission [14]. As the assessment and interpretation of classic SIRS symptoms was hampered in the current 
study population [15, 16], the presence of SIRS was assumed when C2 of the following conditions were 
present:  Body temperature >38.5 °C, leukocyte count <4,000/ll or >12,000/ ll, and volume-resistant shock 
syndrome with the need of epinephrine >30 lg/min.  Pneumonia was assumed to be present if specific signs of 
alveolar infiltrate on chest X-ray and microorganisms from tracheobronchial secretion cultures were present. 
Categorical variables were described using frequency and    percentage.    Patients’    ages    were    given    as 
mean ± standard deviation (SD). PCT levels were given as median ± interquartile range (IQR) due to its variance. 
For statistical analysis, WFNS grade was dichotomized into clinically severe (WFNS 4–5) and non-severe 
(WFNS 1–3) and GOS in unfavorable (GOS 1–3) and favorable (GOS 4–5). Binominal variables were compared 
between the groups by the Fisher’s exact test, and continuous variables by the independent t test. PCT values 
were compared using the Mann–Whitney U or Kruskal–Wallis test, as normal distribution was not present. 
Receiver operating characteristics (ROC) analysis was performed to assess and compare the predictive value of 
early PCT values with known predictors. Sensitivity and specificity were calculated using the cut-off value of 
0.50 ng/ ml for PCT, which has been described as optimal in patients with OHCA [5, 6]. A p value <0.05 was 
regarded as statistically significant. IBM SPSS Statistics 20.0 Software was used. 
 
 
Results  
Out of 231 patients, a total of 109 (47 %) fulfilled the inclusion criteria. The patients’ characteristics are 
summarized in Table 1.  Unfavorable neurological outcome after 3 months was observed in 32 patients (29 %). 
Two of them underwent cardio-pulmonary resuscitation prior to admission. As expected, patients with 
unfavorable outcome presented with clinically and radiologically severe aSAH (both p < 0.01) and tended to 
be more elderly (p = 0.05). The presence of SIRS was higher in patients with unfavorable outcome, however, 
without any statistical significance. Ruptured aneurysm location and the assumed presence of pneumonia at time 
of admission were statistically not different. The results are summarized in Table 1. Systemic PCT levels were 
significantly higher in patients with severe than in patients with non-severe aSAH: 
0.06 ± 0.04 versus 0.11 ± 0.11 lg/l (p < 0.01) (Fig.1a). Patients with radiologically severe aSAH also had higher 
PCT levels; however, there was no statistical significance between   patients   presenting with   Fisher   1–2   and   
3 (Fig. 1b). Furthermore, systemic PCT levels within 24 h after ictus were significantly higher in patients with 
unfavorable compared to patients with favorable outcome: 
0.09 ± 0.13 versus 0.07 ± 0.15 ng/ml (p < 0.01) (Fig.1c). Two   patients   underwent   cardio-pulmonary 
resuscitation prior to admission. Both of them also had a clinically and radiologically severe bleeding. PCT levels 
at admission were 0.29 and 0.68 ng/ml, respectively. Both patients survived. However, functional outcome was 
unfavorable. 
The ROC curve analysis showed an area under the curve (AUC) of 0.66 (p < 0.01; 95 % CI: 0.55–0.77) for PCT, 
0.64   (p = 0.02;   95 %   CI:   0.53–0.75) for   age, 0.83 (p < 0.01; 95 % CI: 0.74–0.91) for WFNS, and 0.68 (p < 
0.05; 95 % CI: 0.57–0.79) for Fisher grade (Fig. 2). Analysis of the combined predictive probability (age, WFNS, 
and Fisher grade) with and without PCT revealed an AUC of 0.88 (p < 0.01; 95 % CI: 0.81–0.91) and 0.87 (p 
< 0.01; 95 % CI:  0.80–0.94), respectively (Fig. 2). Using the PCT cut-off value of 0.50 ng/ml, the sensitivity 
was poor (12 %), while the specificity was high (94 %). The ROC curves are shown in Fig. 2. 
 
 
Discussion 
 
In the current study we intended to assess the predictive value of early PCT values (≤24 h after ictus) with 
regard to the neurological outcome after aSAH.  The results showed increased PCT levels in patients with 
initially severe hemorrhage and in patients with clinically unfavorable outcome. Based on the ROC curve 
analysis, the predictive value of PCT on the neurological outcome was poor to moderate and by that showed to 
be far less predictive than WFNS grade. Comparing the combined predictive probabilities of well-known risk 
factors (WFNS, Fisher grade, and age) with and without PCT, the inclusion of PCT showed virtually no 
advantage. 
Little is known about the origin, liberation kinetics, or pathophysiology of PCT. The acute-phase protein has 
been reported to be a useful biomarker to determine bacterial infection or sepsis [14]. In particular, it has been 
reported to allow discrimination between sepsis and SIRS. However, more recent evidence suggests that PCT 
can also be elevated  under  various  other  ‘‘acute  stress  conditions,’’ such as polytrauma, heat stroke, cardiac 
arrest, burns, traumatic brain injury, and aSAH [8, 9, 14, 17]. Post-cardiac-arrest status has been designated as a 
‘‘sepsis-like’’ syndrome [18, 19]. Moreover, transient myocardial dysfunction can occur after resuscitation, 
mainly as a result of ‘‘myocardial stunning’’ [19], which might further aggravate ischemic–hypoxic brain injury. 
It is of particular interest that high specificity and sensitivity of early PCT values in predicting neurological 
outcome have been reported [5–7, 20]. In particular, PCT levels >0.50 ng/ml at day one after OHCA showed a 
sensitivity of 91.7 % and specificity of 100 % in one study [5]. In another study a sensitivity of 100 % and 
specificity of 81.3 % was reported [6]. ROC curve analysis of the two studies revealed an AUC of 0.98 and 
0.94, respectively [5, 6]. 
The rupture of an intracranial aneurysm is associated with a sudden ICP increase and may reach values as high 
as 162 mmHg [3, 21, 22]. The sharp increase of ICP leads to a decrease of the cerebral perfusion pressure (CPP) 
with a consequent critical decrease of the cerebral blood flow (CBF) [22–24]. In severe hemorrhage, 
intracranial circu- latory arrest lasting for several minutes might occur [22, 25], which might be comparable 
with intracranial circula- tory arrest after OHCA. Furthermore, a ‘‘neurogenic stunned myocardium’’ with 
consecutive cardiac dysfunc- tion might occur, with similar effects as the ‘‘myocardial stunning’’ after OHCA 
[26]. However, with only 2 patients, the number of patients with documented cardio-pulmonary resuscitation in 
the current study population was low. The current results show increased PCT levels in patients with clinically 
and radiologically severe aSAH. It can be assumed that these patients suffered more seriously from cerebral 
circulatory compromise at the time of hemorrhage. The PCT levels probably reflect an acute systemic stress 
response to the hemorrhage. Although patients with unfavorable outcome showed significantly higher PCT 
levels within 24h after ictus, the predictive value for unfavourable neurological outcome was rather poor 
compared to previous reports on patients after OHCA. This might be explained as follows: Early brain injury 
after aSAH cannot be (over-) simplified to transient global cerebral hypoxia due to CBF decrease or arrest. 
There are several patho-physiological mechanisms that activate within minutes after the initial bleeding such as 
mechanical and bio- chemical trauma caused by the hematoma itself [3]. Furthermore, it is well known that 
patients with aSAH are specifically at risk of secondary neurological injury, which may be caused by 1) CVS-
dependent or -independent delayed ischemic events, aka DCI, 2) ‘‘collateral damage’’ in conjunction with the 
aneurysm securement, and/or 3) rebleeding [1, 27]. 
With respect to the current results, following limitations have to be considered. The crucial disadvantage of the 
current study is its anecdotal nature. Furthermore, the database was derived from a single tertiary care center and, 
therefore, might carry the risk of being biased as well as of over representing severe cases. 
 
 
Conclusion  
Early elevated systemic PCT levels in patients with severe aSAH might reflect the overall initial stress 
response. In the current study, patients with unfavorable neurological outcome had higher PCT levels within 24 
h after ictus. However, their predictive value appeared to be poor, especially compared to the reported 
predictive values in patients with OHCA. Therefore, early PCT levels might be of little practical use in 
predicting neurological outcome after aSAH. Furthermore, the results underline once more the 
pathophysiological complexity of neuronal injury after aSAH. 
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Figure legends 
Figure 1. 
PCT levels (≤24h) shown as box-plots. A) Patients with clinically severe SAH (WFNS 4-5) had significantly 
higher PCT levels. B) Patients with radiologically severe SAH had significantly higher PCT levels. There was no 
statistical significance between patients presenting with Fisher grade 1-2 and 3. C) Patients with unfavourable 
outcome (GOS 1-3) had significantly higher PCT levels compared to patients with favourable outcome (GOS 4-
5). PCT levels are logarithmically transformed for illustrative purposes. 
 
Figure 2. 
ROC curves of PCT beside WFNS grade, Fisher grade, and age. The combined predicted probability with PCT 
showed virtually no advantage over that without PCT. 
 
Table 1. Patients characteristics 
  
          
   
All Patietns 
(n=109) 
GOS 1-3 
(n=32) 
GOS 4-5 
(n=77) 
Sig. 
                 
          
Sex         
 Female  67 (62%) 23 (72%) 44 (57%) p=0.196 
 Male  42 (38%) 9 (28%) 33 (43%) 
          
Age  54.0 ± 13.8 58 ± 13.8 52.3 ± 13.5 p=0.050 
          
WFNS Grade         
 1-3  65 (60%) 7 (22%) 58 (75%) p<0.001 
 4-5  44 (40%) 25 (76%) 19 (25%) 
          
Aneurysm location         
 Anterior Circulation  82 (75%) 24 (75%) 58 (75%) p>0.999 
 Posterior Circulation 27 (25%) 8 (25%) 24 (25%) 
          
SIRS  7 (6%) 4 (13%) 3 (4%) p=0.191 
          
Pneumonia  4 (4%) 2 (6%) 2 (3%) p=0.579 
                    
          
GOS indicates Glasgow outcome scale; Sig, significance; SIRS, systemic inflammatory response 
syndrome; WFNS, world federation of neurological surgeons. 
 


